{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:20Z","timestamp":1787008700066,"version":"build-2736575974"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ateneo La Sapienza"},{"name":"Impact of Mavacamten Treatment in Real-world Patients with Obstructive Hypertrophic Cardiomyopathy: Experience from a Tertially Referral Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertrophic cardiomyopathy is a common form of genetic heart disease and in two-thirds of cases is associated with left ventricular outflow tract obstruction. Mavacamten, a selective cardiac myosin ATPase inhibitor, has emerged as the first disease-specific approach able to target the molecular mechanism responsible for this clinical phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 69-year-old woman, admitted for a presyncopal episode, was diagnosed with obstructive hypertrophic cardiomyopathy and treated with beta-blockers at maximal tolerated dose. At follow-up, she was still symptomatic with clinically relevant left ventricular outflow tract obstruction despite treatment and mavacamten was started. After 4\u2005weeks, she reported improved exercise tolerance, with substantial reduction in left ventricular outflow tract gradients and no decline in left ventricular systolic function. Surprisingly, her electrocardiogram (ECG) showed resolution of a pre-existing complete left bundle branch block.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first reported case of complete left bundle branch block resolution during treatment with mavacamten. This finding contributes to the growing evidence on the positive electrical and structural remodelling deriving from mavacamten use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaf592","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:16:45Z","timestamp":1763558205000},"source":"Crossref","is-referenced-by-count":2,"title":["Complete left bundle branch block resolution during treatment with Mavacamten: a case report of a first-in-class scenario"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4311-7570","authenticated-orcid":false,"given":"Giulia","family":"Marchionni","sequence":"first","affiliation":[{"name":"Sapienza Universit\u00e0 di Roma , Viale del Policlinico 155, Roma 00161 ,","place":["Italia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alfarano","sequence":"additional","affiliation":[{"name":"Sapienza Universit\u00e0 di Roma , Viale del Policlinico 155, Roma 00161 ,","place":["Italia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ballatore","sequence":"additional","affiliation":[{"name":"Sapienza Universit\u00e0 di Roma , Viale del Policlinico 155, Roma 00161 ,","place":["Italia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4869-4898","authenticated-orcid":false,"given":"Jacopo","family":"Costantino","sequence":"additional","affiliation":[{"name":"Sapienza Universit\u00e0 di Roma , Viale del Policlinico 155, Roma 00161 ,","place":["Italia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5954-3796","authenticated-orcid":false,"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Sapienza Universit\u00e0 di Roma , Viale del Policlinico 155, Roma 00161 ,","place":["Italia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025120106215940200_ytaf592-B1","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2025120106215940200_ytaf592-B2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2025120106215940200_ytaf592-B3","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"2025120106215940200_ytaf592-B4","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"2025120106215940200_ytaf592-B5","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2025120106215940200_ytaf592-B6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"The Lancet"},{"key":"2025120106215940200_ytaf592-B7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025120106215940200_ytaf592-B8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","article-title":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center","volume":"86","author":"Desai","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2025120106215940200_ytaf592-B9","doi-asserted-by":"crossref","first-page":"e034069","DOI":"10.1161\/JAHA.123.034069","article-title":"Eighteen-month real-world experience using mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population","volume":"13","author":"Ramonfaur","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025120106215940200_ytaf592-B10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"2025120106215940200_ytaf592-B11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0735-1097(23)00770-2","article-title":"96-week cardiac magnetic resonance (cmr) results of treatment with mavacamten from the explorer cohort of the mava-long-term extension (lte) study in patients (pts) with obstructive hypertrophic cardiomyopathy (hcm)","volume":"81","author":"Saberi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025120106215940200_ytaf592-B12","doi-asserted-by":"crossref","first-page":"100710","DOI":"10.1016\/j.jacadv.2023.100710","article-title":"Mavacamten short-term hemodynamic, functional, and electrocardiographic outcomes","volume":"2","author":"Abdelfattah","year":"2023","journal-title":"JACC Adv"},{"key":"2025120106215940200_ytaf592-B13","author":"Dhingra"},{"key":"2025120106215940200_ytaf592-B14","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.hrthm.2024.03.1495","article-title":"Dynamic impact of mavacamten on ecg patterns of left ventricular hypertrophy with left ventricular strain","volume":"21","author":"Austin","year":"2024","journal-title":"Heart Rhythm"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytaf592\/65404506\/ytaf592.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/12\/ytaf592\/65404506\/ytaf592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/12\/ytaf592\/65404506\/ytaf592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:22:05Z","timestamp":1764588125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaf592\/8328955"}},"subtitle":[],"editor":[{"given":"Luis Antonio","family":"Moreno-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Shahrukh","family":"Hashmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Edgar","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Hugo","family":"Rodriguez-Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaf592","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,20]]},"article-number":"ytaf592"}}